Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash & Equivalents (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Cash & Equivalents for 2 consecutive years, with $8.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 26.02% to $8.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a 26.02% decrease, with the full-year FY2024 number at $19.5 million, changed N/A from a year prior.
  • Cash & Equivalents was $8.9 million for Q3 2025 at Pyxis Oncology, down from $10.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $28.0 million in Q1 2024 to a low of $8.9 million in Q3 2025.